difamilast: Clinical Trials

9 trials of difamilast, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 not yet recruiting. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Completed 7, Not yet recruiting 2

Follow difamilast: new trials by email Literature Review of difamilast trials Research Report on difamilast

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
OPA-15406, Vehicle - Atopic Dermatitis (AD)
Phase 3Not yet recruitingOtsuka Pharmaceutical Co., Ltd.1562025-10-012025-09-15
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
OPA-15406, Vehicle - Atopic Dermatitis (AD)
Phase 3Not yet recruitingOtsuka Pharmaceutical Co., Ltd.1982025-09-012025-09-22
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD
0.3% OPA-15406 Ointment, 1% OPA-15406 Ointment, 0% OPA-15406 vehicle - Atopic Dermatitis (AD)
Phase 3CompletedOtsuka Beijing Research Institute2402023-02-172025-03-25
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
1% OPA-15406 Ointment, 0% OPA-15406 Vehicle - Atopic Dermatitis (AD)
Phase 3CompletedOtsuka Beijing Research Institute2702023-02-062025-08-29
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
Difamilast, Placebo - Atopic Dermatitis
Phase 3CompletedAcrotech Biopharma Inc.1532022-10-012024-08-15
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Difamilast - Atopic Dermatitis
Phase 3CompletedAcrotech Biopharma Inc.5422022-09-152024-08-09
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
OPA-15406 - Atopic Dermatitis (AD)
Phase 3CompletedOtsuka Pharmaceutical Co., Ltd.412022-05-232025-03-30
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
0.3% OPA-15406, 1% OPA-15406, Placebos - Atopic Dermatitis
Phase 3CompletedOtsuka Pharmaceutical Co., Ltd.2512019-05-072021-01-25
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
1% OPA-15406, Placebos - Atopic Dermatitis
Phase 3CompletedOtsuka Pharmaceutical Co., Ltd.3642019-03-252021-01-25

Conditions studied

Dermatitis, Atopic (9)

Sponsors

Otsuka Pharmaceutical Co., Ltd. (5)  ·  Acrotech Biopharma Inc. (2)  ·  Otsuka Beijing Research Institute (2)

Countries

Japan (5)  ·  China (2)  ·  United States (2)

Top investigators

Nobuhito Sanada (2)  ·  Osamu Sato (2)  ·  Jianzhong Zhang, PHD (1)  ·  Lin Ma (1)  ·  Takehisa Matsumaru (1)  ·  Uma S Atmuri, MPharm MS (1)  ·  Uma Srinivas Atmuri, MPharm MS (1)

Results publications

PMID 34289086, PMID 39075274, PMID 41171590